An investigative report in The BMJ, a prestigious British medical news journal which has been in print since 1840, has blown the lid on Pfizer’s COVID-19 ‘vaccine’.
Revelations of poor practices at a contract research company helping to carry out Pfizer’s COVID-19 vaccine trial raise questions about data integrity and regulatory oversight, according to investigative journalist Paul D. Thacker.
According to the whistleblower, the Pfizer contractor (among other things):
- falsified data
- unblinded patients
- employed inadequately trained vaccinators
- was slow to follow up on adverse events reported in Pfizer’s pivotal Phase III trials
The shocking revelations come from Brook Jackson, a regional director employed at Ventavia Research Group, who were one of a number of Texas companies contracted by Pfizer to carry out the Phase III trials.
According to Jackson:
‘staff who conducted quality control checks were overwhelmed by the volume of problems they were finding. After repeatedly notifying Ventavia of these problems, Jackson emailed a complaint to the US Food and Drug Administration (FDA). Ventavia fired her later the same day. Jackson has provided The BMJ with dozens of internal company documents, photos, audio recordings, and emails.
The full whistleblower report is reproduced on The BMJ’s web site.
